Cure My Disease

Don't miss your cure!

 Log in / Sign up

Extended trial tests promising Sjögren's syndrome injection

NCT ID NCT04541589

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study continued testing an experimental drug called iscalimab in people with Sjögren's syndrome who had already taken it in a previous trial and seemed to benefit. For about a year, 206 participants received regular injections of one of two doses to closely monitor safety and see how the drug behaved in their bodies. The goal was to gather more information on whether this treatment could help control the disease over a longer period.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SJOGREN'S SYNDROME are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • North GA Rheumatology Group PC

    Suwanee, Georgia, 30024, United States

  • Novartis Investigative Site

    Ciudad Autonoma de Bs As, Buenos Aires, C1055AAF, Argentina

  • Novartis Investigative Site

    CABA, 1426, Argentina

  • Novartis Investigative Site

    Nedlands, Western Australia, 6009, Australia

  • Novartis Investigative Site

    Graz, 8036, Austria

  • Novartis Investigative Site

    Vienna, 1090, Austria

  • Novartis Investigative Site

    Vitória, Espírito Santo, 29055 450, Brazil

  • Novartis Investigative Site

    Juiz de Fora, Minas Gerais, 36010 570, Brazil

  • Novartis Investigative Site

    São Paulo, São Paulo, 01244-030, Brazil

  • Novartis Investigative Site

    Toronto, Ontario, M5T 2S8, Canada

  • Novartis Investigative Site

    Rimouski, Quebec, G5L 5T1, Canada

  • Novartis Investigative Site

    Trois-Rivières, Quebec, G9A 3Y2, Canada

  • Novartis Investigative Site

    Valdivia, Los Ríos Region, 5110683, Chile

  • Novartis Investigative Site

    Santiago, RM, 7500588, Chile

  • Novartis Investigative Site

    Santiago, 7500571, Chile

  • Novartis Investigative Site

    Santiago, 7500710, Chile

  • Novartis Investigative Site

    Medellín, Antioquia, 050001, Colombia

  • Novartis Investigative Site

    Barranquilla, Atlántico, 080002, Colombia

  • Novartis Investigative Site

    Brest, 29200, France

  • Novartis Investigative Site

    Le Kremlin-Bicêtre, 94275, France

  • Novartis Investigative Site

    Lille, 59037, France

  • Novartis Investigative Site

    Strasbourg, 67000, France

  • Novartis Investigative Site

    Bonn, 53105, Germany

  • Novartis Investigative Site

    Dresden, 01307, Germany

  • Novartis Investigative Site

    Freiburg im Breisgau, 79106, Germany

  • Novartis Investigative Site

    Würzburg, 97080, Germany

  • Novartis Investigative Site

    Athens, 115 27, Greece

  • Novartis Investigative Site

    Székesfehérvár, Fejér, 8000, Hungary

  • Novartis Investigative Site

    Szeged, 6720, Hungary

  • Novartis Investigative Site

    Haifa, 3104802, Israel

  • Novartis Investigative Site

    Kfar Saba, 4428164, Israel

  • Novartis Investigative Site

    Ramat Gan, 5265601, Israel

  • Novartis Investigative Site

    Milan, MI, 20132, Italy

  • Novartis Investigative Site

    Pisa, PI, 56124, Italy

  • Novartis Investigative Site

    Nagoya, Aichi-ken, 457 8510, Japan

  • Novartis Investigative Site

    Sasebo, Nagasaki, 857-1195, Japan

  • Novartis Investigative Site

    Kurashiki, Okayama-ken, 710-0824, Japan

  • Novartis Investigative Site

    Chuo Ku, Tokyo, 104 8560, Japan

  • Novartis Investigative Site

    Rotterdam, South Holland, 3015 GD, Netherlands

  • Novartis Investigative Site

    Groningen, 9713 GZ, Netherlands

  • Novartis Investigative Site

    Lisbon, 1050-034, Portugal

  • Novartis Investigative Site

    Lisbon, 1649 035, Portugal

  • Novartis Investigative Site

    Ponte de Lima, 4990 041, Portugal

  • Novartis Investigative Site

    Brasov, 500283, Romania

  • Novartis Investigative Site

    Cluj-Napoca, 400006, Romania

  • Novartis Investigative Site

    Kazan', 420097, Russia

  • Novartis Investigative Site

    Moscow, 115522, Russia

  • Novartis Investigative Site

    Saint Petersburg, 195257, Russia

  • Novartis Investigative Site

    Tomsk, 634009, Russia

  • Novartis Investigative Site

    Yekaterinburg, 620028, Russia

  • Novartis Investigative Site

    Seoul, Seocho Gu, 06591, South Korea

  • Novartis Investigative Site

    Stockholm, SE, 113 65, Sweden

  • Novartis Investigative Site

    Ankara, 06500, Turkey (Türkiye)

  • Novartis Investigative Site

    Birmingham, B15 2TH, United Kingdom

  • Novartis Investigative Site

    Doncaster, DN2 5LT, United Kingdom

  • Novartis Investigative Site

    Manchester, M13 9WL, United Kingdom

  • Ochsner Health System

    Baton Rouge, Louisiana, 70809, United States

  • Perelman School of Medicine

    Philadelphia, Pennsylvania, 19104, United States

  • The John Hopkins Jerome L Greene Sjogren

    Baltimore, Maryland, 21224, United States

  • Tufts School of Dental Medicine

    Boston, Massachusetts, 02111, United States

  • Uni Wisconsin School Med Pub Health

    Madison, Wisconsin, 53792, United States

  • Winthrop University Hospital

    Mineola, New York, 11501, United States

Conditions

Explore the condition pages connected to this study.

SJOGREN'S SYNDROME